Skip to Main Content
Qurgen Qurgen
Menu Button

Apr. 2026

Brand Icon
In April 2026, minimal Grade 2 infusion related reactions (IRRs) were observed in all patients enrolled in the ongoing Qurgen Clinical trial with 48-hour continuous IV infusion using an infusion pump. This new drug infusion regimen significantly enhanced the safety of SON-DP drug.

Recent news & press

May 21, 2026
Prof Jianjun Wang was invited to attend Tigermed's ASCO Pre-Event Webinar as a Speaker to...
Learn More
Mar. 2026
Qurgen reported that numbers of patients with advanced solid tumors had received low-dose SON-DP treatment...
Learn More